UBS Maintains Buy on McKesson, Raises Price Target to $1200
10/16/2026
Impact: 75
Healthcare
UBS analyst Kevin Caliendo has maintained a 'Buy' rating on McKesson (NYSE: MCK) and increased the price target from $1080 to $1200. This adjustment reflects positive expectations for the company's performance.
AI summary, not financial advice
Share: